BMO Capital notes that on Monday, Roche (RHHBY) announced the proposed acquisition of Carmot Therapeutics for up to $3.1B, focused on the company’s incretin portfolio driving Terns Pharmaceuticals (TERN) shares up given the readthrough to its oral GLP-1. The firm continues to view Terns as a compelling opportunity given its oral GLP-1, TERN-601, ahead of the second half of 2024 Phase 1 data readout. BMO reiterates an Outperform rating on Tern’s stock with a price target of $18 as it believes Terns is well-positioned to participate in obesity market upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TERN:
- Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
- Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
- Terns Pharmaceuticals price target lowered to $10 from $17 at Mizuho
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Terns Pharmaceuticals reports Q3 EPS (42c), consensus (31c)
